# Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

Source: https://onco.cc/trials/nct06425133/  
OnCo record `nct06425133` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of regorafenib in colorectal cancer, run by Centre Hospitalier Universitaire de Besancon, now recruiting.

## Summary

Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers is a phase 2, randomised interventional study registered as NCT06425133 by Centre Hospitalier Universitaire de Besancon, with a registry enrolment figure of 174 participants, started 2024-07-19 and due to reach its primary completion in 2027-09. Interventions recorded: Blood sample; Quality of life questionnaires; Biopsy; Regorafenib; Regorafenib + metronomic chemotherapy. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: To evaluate the impact of a Regorafenib combined with metronomic chemotherapy and low-dose aspirin compared to standard Regorafenib treatment by assessing progression-free survival. Colorectal eligibility wording from the registry: "Patients with histologically proven metastatic colorectal cancer in progression after previous standard treatments (5FU, CPT11 (Irinotecan), oxaliplatin, anti-VEGF (vascular endothelial growth factor), trifluridine/tipiracil, anti-EGFR (epidermal growth factor receptor) therapy if KRAS (Kirsten rat ". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CARE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06425133
- Phase: 2
- Setting: Impact of Regorafenib in Combination With Multimodal Metronomic Chemotherapy on Progression-free Survival Compared With Standard Regorafenib for the Treatment of Chemo-resistant Metastatic Colorectal Cancers
- Sponsor: Centre Hospitalier Universitaire de Besancon
- Enrolled: 174

## Sources

- ClinicalTrials.gov NCT06425133: https://clinicaltrials.gov/study/NCT06425133

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06425133.json